Why macrophages matter in the fight against cystic fibrosis
ImmuONE
May 23, 2023
Lung macrophages play a significant role in the chronic inflammation associated with cystic fibrosis
De-risking nasal & pulmonary formulation development
To deliver therapeutics effectively to the nasal and pulmonary regions, developers must address the physiological barriers in these tissues.
This webinar covers how formulation techniques and early in vitro toxicology work together to accelerate development and reduce risk.
It explains the value of confirming structural and functional integrity early, highlights the benefits of spray‑drying for stability, particle control, and excipient incorporation, and outlines how toxicology and permeability testing provide evidence of safety and therapeutic potential.
Watch the full webinar
Watch the webinar to explore insights that support informed development and formulation assessment.
Speak to the team
If you’d like to discuss ImmuONE’s capabilities in nasal and pulmonary in vitro assessment, please contact the team.
Add a Comment
Related Posts
Why in vitro methods are the future of risk assessments for inhaled substances
ImmuONE
October 5, 2023
Inhaled substances are primarily tested on rats for toxicity, but key differences between rat and human lungs suggest it’s time to look towards alternative methods.
Using an animal-free assay
ImmuONE
April 13, 2023
We’ve just returned from the Society of Toxicology conference in Nashville, where we were excited to exhibit our upcoming in vitro cell culture models.